Core Insights - TC BioPharm has reported positive safety data for its TCB008 treatment, allowing for exploration of higher doses in the ACHIEVE UK Trial [1][2] - The company is actively recruiting patients for both Cohort A and Cohort B in the ACHIEVE study, with plans to increase the TCB008 dose from 230 million to 819 million Gamma Delta T-Cells [2][3] - The company aims to identify the optimal biologically effective dose for patients who have exhausted other treatment options [4] Patient Recruitment and Study Progress - Over half of the Cohort A patients in Stage One of the ACHIEVE study have received TCB008, addressing an unmet clinical need for patients unable to achieve remission with existing treatments [2] - Cohort B patients, who have residual disease after initial remission, are being recruited at the current TCB008 dose of 230 million Gamma Delta T-Cells across four active clinical trial sites [3] - Two additional clinical trial sites are expected to be onboarded in the first half of 2025, increasing the total to six sites in the UK [3] Manufacturing and Operational Improvements - The company is focused on scaling up the manufacturing process to support the increased TCB008 dose, which is being developed by Dr. Lauren Bor's team [4] - Operational teams are collaborating to enhance the manufacturing process, aiming for increased yields and economic efficiencies in 2025 [5] Company Overview - TC BioPharm is a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies for cancer treatment, with a focus on acute myeloid leukemia [6][7] - The company is recognized as a leader in developing gamma-delta T cell therapies and is conducting pivotal clinical trials using its proprietary allogeneic CryoTC technology [8]
TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial